Search - tctmd.com

Displaying 1 - 20 of 66

Sort: Relevancy | Date

CVD Benefits of Activity Seen Below Widely Quoted Step Goal in Older Adults

News Daily News

CVD Benefits of Activity Seen Below Widely Quoted Step Goal in Older Adults

Michael O'Riordan

December 28, 2022

December 2022 News Roundup

News Opinion CV Team Dispatch

December 2022 News Roundup

December 28, 2022

‘Digital Biomarker,’ Derived From EHR, Can Diagnose and Describe CAD

News Daily News

‘Digital Biomarker,’ Derived From EHR, Can Diagnose and Describe CAD

Yael L. Maxwell

December 27, 2022

Not Just Hot, but Also Cold Weather Extremes Linked to More CV Deaths

News Daily News

Not Just Hot, but Also Cold Weather Extremes Linked to More CV Deaths

December 15, 2022

Exposure to Lead Linked to Risk of CVD Mortality: Strong Heart Study

News Daily News

Exposure to Lead Linked to Risk of CVD Mortality: Strong Heart Study

Michael O'Riordan

November 18, 2022

Endothelin Receptor Antagonist Effective in Resistant Hypertension: PRECISION

News Conference News AHA 2022

Endothelin Receptor Antagonist Effective in Resistant Hypertension: PRECISION

Michael O'Riordan

November 09, 2022

STRONG-HF: Rapid Uptitration of GDMT After Acute HF Pays Dividends

News Conference News AHA 2022

STRONG-HF: Rapid Uptitration of GDMT After Acute HF Pays Dividends

November 07, 2022

EMPA-KIDNEY: Empagliflozin a ‘Win’ for Patients With CKD

News Conference News AHA 2022

EMPA-KIDNEY: Empagliflozin a ‘Win’ for Patients With CKD

November 06, 2022

BRIGHT-4: Large, ‘Clean’ Trial Clarifies Bivalirudin Benefits in STEMI

News Conference News AHA 2022

BRIGHT-4: Large, ‘Clean’ Trial Clarifies Bivalirudin Benefits in STEMI

November 06, 2022

IRONMAN Misses but Lends Support to IV Iron Repletion in HF

News Conference News AHA 2022

IRONMAN Misses but Lends Support to IV Iron Repletion in HF

November 05, 2022

Extreme BP-Lowering Harmful After Stroke Thrombectomy: ENCHANTED2/MT

News Daily News

Extreme BP-Lowering Harmful After Stroke Thrombectomy: ENCHANTED2/MT

November 01, 2022

AI-ECG Strategy Identifies Patients at Risk for AF

News Daily News

AI-ECG Strategy Identifies Patients at Risk for AF

September 30, 2022

COVID-19: TCTMD’s Dispatch for September 26

News Daily News

COVID-19: TCTMD’s Dispatch for September 26

September 26, 2022

FAME 3 Substudies: Clinical Outcomes Related to Anatomic vs Functional Significance and Prognostic Value of Post-PCI FFR II

Presentation TCT 2022

FAME 3 Substudies: Clinical Outcomes Related to Anatomic vs Functional Significance and Prognostic Value of Post-PCI FFR II

Presenter: Zsolt Piroth

September 19, 2022

FAME 3 Substudies: Clinical Outcomes Related to Anatomic vs Functional Significance and Prognostic Value of Post-PCI FFR

Presentation TCT 2022

FAME 3 Substudies: Clinical Outcomes Related to Anatomic vs Functional Significance and Prognostic Value of Post-PCI FFR

Presenter: Yuhei Kobayashi

September 19, 2022

A Randomised Controlled Trial Assessing the Value of Computed Tomography Cardiac Angiography (CTCA) in Improving Patient Satisfaction and Reducing Contrast Load, Procedural Duration, and Complications in Patients Who Had CABG

Presentation TCT 2022

A Randomised Controlled Trial Assessing the Value of Computed Tomography Cardiac Angiography (CTCA) in Improving Patient Satisfaction and Reducing Contrast Load, Procedural Duration, and Complications in Patients Who Had Previous Bypass Operation (CABG)…

Presenter: Daniel Jones

September 19, 2022

Survival After PCI or CABG for Left Main Coronary Disease: A Report From the Swedish Coronary Angiography and Angioplasty Registry

Presentation TCT 2022

Survival After PCI or CABG for Left Main Coronary Disease: A Report From the Swedish Coronary Angiography and Angioplasty Registry

Presenter: Elmir Omerovic

September 19, 2022

Everolimus-Eluting Stents or Bypass Surgery for Mutivessel Coronary Artery Disease: 10-Year Outcomes of Multicenter Randomized Controlled BEST Trial

Presentation TCT 2022

Everolimus-Eluting Stents or Bypass Surgery for Mutivessel Coronary Artery Disease: 10-Year Outcomes of Multicenter Randomized Controlled BEST Trial

Presenter: Jung-Min Ahn

September 19, 2022

SYMPLICITY HTN-3’s Late Surprise: Sustained BP Drop at 3 Years Despite Earlier Miss

News Conference News TCT 2022

SYMPLICITY HTN-3’s Late Surprise: Sustained BP Drop at 3 Years Despite Earlier Miss

Michael O'Riordan

September 19, 2022

Case-Based Presentation: Sex-Specific Considerations of Physiologic Assessment of CAD in the Cath Lab

Presentation TCT 2022

Case-Based Presentation: Sex-Specific Considerations of Physiologic Assessment of CAD in the Cath Lab

Presenter: Rasha Al-Lamee

September 17, 2022

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.